Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bionano Genomics Inc (NQ: BNGO )

0.9833 +0.0333 (+3.51%)
Streaming Delayed Price Updated: 11:34 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bionano Genomics Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Bionano Genomics Stock Can Regain the Crucial $5 Level
Bionano Genomics is working hard to address rare diseases, yet Wall Street doesn't see the value in BNGO stock -- but that could change soon. 
Via InvestorPlace
Bionano Genomics May Finally Offer a Reward for Your Risk
BNGO stock has been a falling knife for the past year. But, with promising fundamentals and good tailwinds, now be the time to take a chance. 
Via InvestorPlace
Hold On to Bionano Genomics Stock Until It Reaches $6 at Least
After a year of blockbuster revenue growth, BNGO stock deserves a major re-rating 
Via InvestorPlace
Bionano Genomics's Return On Capital Employed Insights
Benzinga Pro data, Bionano Genomics (NASDAQ:BNGO) reported Q4 sales of $6.30 million. Earnings fell to a loss of $22.95 million, resulting in a 10.58% decrease from last quarter... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Bionano Genomics's Earnings Outlook
Bionano Genomics (NASDAQ:BNGO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Bionano Genomics Has Attractive Applications But An Unattractive Stock Price
BNGO stock will witness more hard times until profitability is improved and sales start to rebound. That could take some time. 
Via InvestorPlace
Bionano Stock Looks to Have a Monster Comeback in Its Future
Bionano's Saphyr appears to be able to help doctors treat leukemia, and the adoption of its device is growing rapidly. 
Via InvestorPlace
Investors Have Cast Their ‘No’ Votes Against Bionano Genomics
A preliminary report from Bionano Genomics doesn't tell the full story and a lack of profitability will likely weigh on BNGO stock. 
Via InvestorPlace
Bionano Is Not the Genomics Stock To Bet On
Bionano's recent results are lackluster and point to more volatility ahead for BNGO stock. Best to just avoid this stock for now. 
Via InvestorPlace
Bionano Genomics Is Interesting as Genome Testing Scales Upwards
BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing. 
Via InvestorPlace
Bionano Genomics Preliminary Q4, FY21 Revenue Exceed Expectations
Bionano Genomics Inc (NASDAQ: BNGO) posted preliminary Q4 sales of $5.8 million - $6.2 million, +25% - 33% sequentially, up 45% - 55% Y/Y, and above the consensus... 
Via Benzinga
7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now
These cheap stocks under $10 are poised to rally in the new, more friendly macro environment that's in place as 2022 unfolds. 
Via InvestorPlace
Bionano Genomics Stock Is a Low-Priced Bet on Sound Science
Even though BNGO stock investors struggled in 2021, prepare for new price discovery as Bionano pushes the envelope in optical genome mapping. 
Via InvestorPlace
The Critics Are Wrong About Bionano Stock
The critics of Bionano are greatly underestimating the vast potential of Saphyr and of BNGO stock for long-term investors. 
Via InvestorPlace
This Analyst’s Saphyr Calculations Suggest Buying Bionano While It’s Down
If BNGO stock reaches Oppenheimer’s price target, investors are looking at a return of more than 300%, plus long-term growth potential. 
Via InvestorPlace
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ... 
Via Benzinga
Bionano Genomics Proves Not Everything Genetic is Gold
Bionano sells a $150,000 machine called Saphyr that does genetic mapping. It's a solid device, but its future remains in the future, as do BNGO stock fortunes. 
Via InvestorPlace
Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ: 
Via Benzinga
Wait for Bionano Stock to Fall Further Before Buying
BNGO stock is breaking down following the latest earnings report, and there are no major catalysts to push shares up in the short term. 
Via InvestorPlace
Bionano’s Is on Track for Growth Thanks to Saphyr
BNGO stock beats analyst forecasts yet again. Flush with cash and with Saphyr installations rising, this stock remains a high potential play. 
Via InvestorPlace
With Progress on Multiple Fronts, Bionano Genomics Stock Is Great Buy Here
Bionano's acquisition of a software company makes Saphyr more attractive, and studies should result in insurers reimbursing those who use the system. BNGO stock is a buy. 
Via InvestorPlace
Bionano Genomics, Inc (BNGO) Q3 2021 Earnings Call Transcript
BNGO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock increased by 16.73% to $14.86 during Tuesday's regular session. The current volume of 1.0 million shares is 269.7%... 
Via Benzinga
2 Best Biotech Stocks to Buy in November
Bionano Genomics and Ocugen could both be gearing up for a healthy rally this month. 
Via The Motley Fool
Bionano Genomics Is Still Set to Pay Off Big for Patient Investors
BNGO stock is no longer a fast money trade. But that's hardly a reason to skip out on it, given its massive potential. 
Via InvestorPlace
Jim Cramer Prefers This Stock Over Mogo, Considers Endeavor Group As Inexpensive
On CNBC’s "Mad Money Lightning Ro... 
Via Benzinga
Bionano Genomics’ Latest Software Business Acquisition Adds Immense Value
BNGO stock isn't a darling of the markets at the moment, but Bionano continues to advance its stature in the optical genome mapping niche. 
Via InvestorPlace
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.